Corcept Therapeutics

corcept.com

Corcept Therapeutics is a biopharmaceutical company focused on cortisol modulation, leading the research and development of cortisol modulators that regulate cortisol activity at the glucocorticoid receptor (GR). With over 25 years of experience, the company has discovered more than 1,000 selective proprietary cortisol modulators and received FDA approval for Korlym® (mifepristone), the first treatment for hypercortisolism. Corcept is currently conducting more than 30 ongoing studies across various disease areas, including endocrinology, oncology, metabolism, and neurology, positioning itself as a leader in the field of cortisol modulation and aiming to revolutionize the treatment of serious diseases.